Deerfield Management Company, L.P. (Series C) Sarepta Therapeutics, Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$63.15 - $90.42 $8.9 Million - $12.7 Million	-141,000 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$77.28 - $99.42 $10.9 Million - $14 Million	141,000 New	141,000 $12.7 Million
Q2 2020 Aug 14, 2020	SELL	$93.0 - $171.7 $21.9 Million - $40.3 Million	-235,000 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$82.38 - $131.64 $2.06 Million - $3.29 Million	25,000 Added 11.9%	235,000 $23 Million
Q4 2019 Feb 14, 2020	SELL	$76.53 - $135.58 $13.2 Million - $23.3 Million	-172,000 Reduced 45.03%	210,000 $27.1 Million
Q3 2019 Nov 14, 2019	BUY	$72.81 - $156.91 $5.31 Million - $11.5 Million	72,975 Added 23.61%	382,000 $28.8 Million
Q2 2019 Aug 14, 2019	SELL	$112.21 - $151.95 $8.64 Million - $11.7 Million	-76,975 Reduced 19.94%	309,025 $47 Million
Q1 2019 May 15, 2019	BUY	$106.67 - $151.68 $4.71 Million - $6.7 Million	44,200 Added 12.93%	386,000 $46 Million
Q4 2018 Feb 14, 2019	BUY	$97.32 - $148.76 $4.46 Million - $6.81 Million	45,800 Added 15.47%	341,800 $37.3 Million
Q2 2018 Aug 14, 2018	BUY	$71.74 - $153.69 $21.2 Million - $45.5 Million	296,000 New	296,000 $39.1 Million

Others Institutions Holding SRPT

# of Institutions

530

Shares Held

84.5M

Call Options Held

2.06M

Put Options Held

1.52M

Black Rock Inc. New York, NY

10.3M
Shares

$1.31 Billion
0.04% of portfolio
Vanguard Group Inc Valley Forge, PA

8.97M
Shares

$1.14 Billion
0.02% of portfolio
Capital International Investors Los Angeles, CA

6.26M
Shares

$793 Million
0.16% of portfolio
Janus Henderson Group PLC London, X0

4.36M
Shares

$552 Million
0.29% of portfolio
State Street Corp Boston, MA

4.27M
Shares

$541 Million
0.02% of portfolio

View Full List

About Sarepta Therapeutics, Inc.

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $11.1B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

More about SRPT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account